Safety and efficacy of selective serotonin reuptake inhibitors in the treatment of children and adolescents compared to adults;Sicherheit und wirksamkeit von serotonin-wiederaufnahmehemmern in der behandlung von kindern und jugendlichen im vergleich zu erwachsenen

Neuropsychiatrie

Volumn 19, Issue 1, 2005, Pages 34-39

  Aichhorn, Wolfgang ^a,c   Geretsegger, Ch ^b  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b Paracelsus MPU Salzburg   (Austria)

^c Univ Klinik für Psychiatrie   (Austria)

Author keywords

Adolescents; Children; Depression; SSRI; Suicidality

Indexed keywords

FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; HUMAN; OBSESSIVE COMPULSIVE DISORDER;

EID: 24944549012     PISSN: 09486259     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Food and Drug Administration. Public health advisory: suicidality in children and adolescents being treated with antidepressant medications, http://www.fda.gov/cder/ drug/antidepressants/SSRIPHA200410. htm. 2004.
2. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004; 363: 1341-1345.
3. Olfson M, Shaffer D, Marcus SC, Greenberg T. Relationship between antidepressant medication treatment and suicide in adolescents. Archives of General Psychiatry 2003; 60: 978-982.
4. Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant medication use and rate of suicide. Archives of General Psychiatry 2005; 62: 165-172.
5. Essau CA, Karpinski NA, Petermann F, Conradt J. Incidence and comorbidity of mental disorders in adolescents - Results of the Bremen Youth Study. Zeitschrift fur Klinische Psychologie Psychiatrie und Psychotherapie 1998; 46: 105-124.
6. Lewinsohn PM, Clarke GN, Seeley JR, Rohde P. Major depression in community adolescents: age at onset, episode duration, and time to recurrence. J. Am. Acad. Child Adolesc. Psychiatry 1994; 33: 809-818.
7. Rao U, Ryan ND, Birmaher B, Dahl RE, Williamson DE, Kaufman J, Rao R, Nelson B. Unipolar depression in adolescents: clinical outcome in adulthood. J. Am. Acad. Child Adolesc. Psychiatry 1995; 34: 566-578.
8. Geller DA, Biederman J, Stewart SE, Mullin B, Martin A, Spencer T, Faraone SV. Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. American Journal of Psychiatry 2003; 160: 1919-1928.
9. Geller DA, Wagner KD, Emslie G, Murphy T, Carpenter DJ, Wetherhold E, Perera P, Machin A, Gardiner C. Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: A randomized, multicenter, double-blind, placebo-controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry 2004; 43: 1387-1396.
10. Masi G, Toni C, Mucci M, Millepiedi S, Mata B, Perugi G. Paroxetine in child and adolescent outpatients with panic disorder. Journal of Child and Adolescent Psychopharmacology 2001; 11: 151-157.
11. Cheer SM, Figgitt DR. Spotlight on fluvoxamine in anxiety disorders in children and adolescents. Cns Drugs 2002; 16: 139-144.
12. Birmaher B, Axelson DA, Monk K, Kalas C, Clark DB, Ehmann M, Bridge J, Heo J, Brent DA. Fluoxetine for the treatment of childhood anxiety disorders. J. Am. Acad. Child Adolesc. Psychiatry 2003; 42: 415-423.
13. Wagner KD, Berard R, Stein MB, Wetherhold E, Carpenter DJ, Perera P, Gee M, Davy K, Machin A. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Archives of General Psychiatry 2004; 61: 1153-1162.
14. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T, Rintelmann J. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Archives of General Psychiatry 1997; 54: 1031-1037.
15. Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown E, Nilsson M, Jacobson JG. Fluoxetine for acute treatment of depression in children and adolescents: A placebo-controlled, randomized clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry 2002; 41: 1205-1215.
16. Emslie GJ, Heiligenstein JH, Hoog SL, Wagner KD, Findling RL, McCracken JT, Nilsson ME, Jacobson JG. Fluoxetine treatment for prevention of relapse of depression in children and adolescents: A doubleblind, placebo-controlled study. Journal of the American Academy of Child and Adolescent Psychiatry 2004; 43: 1397-1405.
17. Birmaher B, Brent DA, Kolko D, Baugher M, Bridge J, Holder D, Iyengar S, Ulloa RE. Clinical outcome after short-term psychotherapy for adolescents with major depressive disorder. Arch. Gen. Psychiatry 2000; 57: 29-36.
18. March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Bums B, Domino M, Vitiello B, Severe J. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression - Treatment for adolescents with depression study (TADS) randomized controlled trial. Jama-Journal of the American Medical Association 2004; 292: 807-820.
19. Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B, Hagino OR, Koplewicz H, Carlson GA, Clarke GN, Emslie GJ, Feinberg D, Geller B, Kusumakar V, Papatheodorou G, Sack WH, Sweeney M, Wagner DK, Weller EB, Winters NC, Oakes R, McCafferty JP. Efficacy of paroxetine in the treatment of adolescent major depression: A randomized, controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry 2001; 40: 762-772.
20. Wagner KD, Ambrosini P, Rynn M, Wohlberg C, Yang RY, Greenbaum MS, Childress A, Donnelly C, Deas D. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder - Two randomized controlled trials. Jama-Journal of the American Medical Association 2003; 290: 1033-1041.
21. Wagner KD, Robb AS, Findling RL, Jin JQ, Gutierrez MM, Heydorn WE. A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. American Journal of Psychiatry 2004; 161: 1079-1083.
22. Birmaher B, Ryan ND, Williamson DE, Brent DA, Kaufman J, Dahl RE, Perel J, Nelson B. Childhood and adolescent depression: A review of the past 10 years. 1. Journal of the American Academy of Child and Adolescent Psychiatry 1996; 35: 1427-1439.
23. Birmaher B, Ryan ND, Williamson DE, Brent DA, Kaufman J. Childhood and adolescent depression: A review of the past 10 years. 2. Journal of the American Academy of Child and Adolescent Psychiatry 1996; 35: 1575-1583.
24. Geller B, Reising D, Leonard HL, Riddle MA, Walsh BT. Critical review of tricyclic antidepressant use in children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry 1999; 38: 513-516.
25. Teicher MH, Glod C, Cole JO. Emergence of Intense Suicidal Preoccupation During Fluoxetine Treatment. American Journal of Psychiatry 1990; 147: 207-210.
26. Beasley CM, Jr., Dornseif BE, Bosomworth JC, Sayler ME, Rampey AH, Jr., Heiligenstein JH, Thompson VL, Murphy DJ, Masica DN. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ 1991; 303: 685-692.
27. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J. Affect. Disord. 2000; 58: 19-36.
28. Burke WJ. Selective versus multi-transmitter antidepressants: are two mechanisms better than one? J. Clin. Psychiatry 2004; 65 Suppl 4: 37-45.
29. Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials - An analysis of the food and drug administration database. Archives of General Psychiatry 2000; 57: 311-317.
30. Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: Analysis of FDA reports. American Journal of Psychiatry 2003; 160: 790-792.
31. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ 2005; 330: 385.
32. Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, Hutton B. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ 2005; 330: 396.
33. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. Jama-Journal of the American Medical Association 2004; 292: 338-343.
34. Martinez C, Rietbrock S, Wise L, Ashby D, Chick J, Moseley J, Evans S, Gunnell D. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. British Medical Journal 2005; 330: 389-393.